We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
Read MoreHide Full Article
Abiomed, Inc. recently announced that it has successfully treated the first patient in Japan with Impella 5.5 with SmartAssist. The male patient on whom the procedure took place was treated for cardiogenic shock.
In the same press release, the company confirmed reaching the global milestone of treating over 5,000 patients. The milestone procedure was performed at a hospital in Atlanta, GA on a female patient with cardiomyopathy.
With the continued adoption of the Impella 5.5 with SmartAssist, Abiomed’s foothold is likely to be strengthened in the global coronary business.
Significance of the Successful Usage
Per the management of the Japanese facility where the first patient was treated, the successful usage of the Impella 5.5 with SmartAssist is expected to provide a minimally invasive surgical option for its acute heart failure patients.
Besides the various features of the Impella 5.5 with SmartAssist, the usage of the device also facilitates round-the-clock patient monitoring. More than 90% of patients are securely monitored in the cloud via Impella Connect, thereby giving care providers access to Impella status data at any time of the day or night.
It is also noteworthy to mention that a study of 200 patients treated with Impella 5.5 with SmartAssist at 42 medical centers in the United States indicated a 74% survival to explant, with 58% of those patients achieving native heart recovery.
Industry Prospects
Per a report by Research and Markets, the global heart pump device market is anticipated to reach $5.5 billion by 2026 from $2.1 billion in 2021 at a CAGR of 21.6%. Factors like rising prevalence of cardiovascular diseases and long waiting periods for heart transplants are likely to drive the market.
Given the market potential, continued adoption of Impella is likely to provide a significant boost to Abiomed’s business globally.
Notable Developments
In February, Abiomed reported its third-quarter fiscal 2022 results, wherein it saw continued strength in its global Impella revenues.
In January, the company announced successful results of the first-in-human early feasibility study of the preCARDIA system, which has been designed to improve decongestion in acutely decompensated heart failure patients by intermittently occluding the superior vena cava.
The same month, Abiomed received the FDA’s grant of an Early Feasibility Study Investigational Device Exemption to Impella BTR (Bridge-to-Recovery). At the same time, the company received approval from Japan’s Pharmaceuticals and Medical Devices Agency and Hong Kong’s Medical Device Division for Impella 5.5 with SmartAssist.
Price Performance
Shares of the company have lost 5.6% in the past year against the industry’s 0.9% growth and the S&P 500's 8.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, Abiomed carries a Zacks Rank #2 (Buy).
A few other stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 36.7% against the industry’s 55.2% fall over the past year.
Edwards Lifesciences, carrying a Zacks Rank #2, has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.5%.
Edwards Lifesciences has gained 44.4% compared with the industry’s 0.9% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 29.1% compared with the industry’s 9.8% growth over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abiomed (ABMD) Announces Successful Usage of Impella in Japan
Abiomed, Inc. recently announced that it has successfully treated the first patient in Japan with Impella 5.5 with SmartAssist. The male patient on whom the procedure took place was treated for cardiogenic shock.
In the same press release, the company confirmed reaching the global milestone of treating over 5,000 patients. The milestone procedure was performed at a hospital in Atlanta, GA on a female patient with cardiomyopathy.
With the continued adoption of the Impella 5.5 with SmartAssist, Abiomed’s foothold is likely to be strengthened in the global coronary business.
Significance of the Successful Usage
Per the management of the Japanese facility where the first patient was treated, the successful usage of the Impella 5.5 with SmartAssist is expected to provide a minimally invasive surgical option for its acute heart failure patients.
Besides the various features of the Impella 5.5 with SmartAssist, the usage of the device also facilitates round-the-clock patient monitoring. More than 90% of patients are securely monitored in the cloud via Impella Connect, thereby giving care providers access to Impella status data at any time of the day or night.
It is also noteworthy to mention that a study of 200 patients treated with Impella 5.5 with SmartAssist at 42 medical centers in the United States indicated a 74% survival to explant, with 58% of those patients achieving native heart recovery.
Industry Prospects
Per a report by Research and Markets, the global heart pump device market is anticipated to reach $5.5 billion by 2026 from $2.1 billion in 2021 at a CAGR of 21.6%. Factors like rising prevalence of cardiovascular diseases and long waiting periods for heart transplants are likely to drive the market.
Given the market potential, continued adoption of Impella is likely to provide a significant boost to Abiomed’s business globally.
Notable Developments
In February, Abiomed reported its third-quarter fiscal 2022 results, wherein it saw continued strength in its global Impella revenues.
In January, the company announced successful results of the first-in-human early feasibility study of the preCARDIA system, which has been designed to improve decongestion in acutely decompensated heart failure patients by intermittently occluding the superior vena cava.
The same month, Abiomed received the FDA’s grant of an Early Feasibility Study Investigational Device Exemption to Impella BTR (Bridge-to-Recovery). At the same time, the company received approval from Japan’s Pharmaceuticals and Medical Devices Agency and Hong Kong’s Medical Device Division for Impella 5.5 with SmartAssist.
Price Performance
Shares of the company have lost 5.6% in the past year against the industry’s 0.9% growth and the S&P 500's 8.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Currently, Abiomed carries a Zacks Rank #2 (Buy).
A few other stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 36.7% against the industry’s 55.2% fall over the past year.
Edwards Lifesciences, carrying a Zacks Rank #2, has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.5%.
Edwards Lifesciences has gained 44.4% compared with the industry’s 0.9% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 29.1% compared with the industry’s 9.8% growth over the past year.